ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2637

A Novel Regulatory Antigen Presenting B Cell and Memory Regulatory T Cell Subsets Are Enriched during the Quiescent Phase of Childhood Onset Systemic Lupus Erythematosus

Joo Guan Yeo1,2, Thaschawee Arkachaisri1,3, Lena Das1, Justin Hung Tiong Tan1, Jing Yao Leong2, Yun June Angela Tan4, Liyun Lai5, Loshinidevi D/O Thana Bathi2, Phyllis Chen2, Seck Choon Elene Lee1, Yun Xin Book1 and Salvatore Albani5,6, 1Rheumatology and Immunology Service, KK Women's and Children's Hospital, Singapore, Singapore, 2Singhealth Translational Immunology and Inflammation Centre (STIIC), Duke-NUS Medical School, Singapore, Singapore, 3Duke-NUS Medical School, Singapore, Singapore, 4Department of Paediatric Anaesthesia, KK Women's and Children's Hospital, Singapore, Singapore, 5SingHealth Translational Immunology and Inflammation Centre (STIIC), Duke-NUS Medical School, Singapore, Singapore, 6KK Women's and Children's Hospital, Singapore, Singapore

Meeting: 2017 ACR/ARHP Annual Meeting

Date of first publication: September 18, 2017

Keywords: CyTOF, pediatrics and regulatory cells, SLE

  • Tweet
  • Email
  • Print
Session Information

Date: Tuesday, November 7, 2017

Title: Systemic Lupus Erythematosus – Human Etiology and Pathogenesis Poster II

Session Type: ACR Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose:

Systemic Lupus Erythematosus (SLE) is a multi-factorial disease and the conventional oligo-dimensional investigative approach involving one or a few cell subsets at a time is inadequate for its study. We hypothesize that multiple immunological abnormalities contribute to lupus pathogenesis and hence, a comprehensive holistic interrogative strategy is required. To address these issues, we employ a multi-dimensional, deep immunophenotyping approach using mass cytometry to unravel the pathogenic mechanism underpinning childhood onset SLE (cSLE).

Methods:

Peripheral blood mononuclear cells from 14 cSLE patients and 14 healthy paediatric controls, were stained with 37 immune phenotypic markers for mass cytometry. Subsequent analysis of the data was done with dimensional reductions followed by automated cell classification, clustering and visualization using an in-house customized machine learning software (MARVis: Multi-dimensional Automated Reduction and Visualization). Unique nodes representing immune subsets enriched in cSLE patients were statistically evaluated with reference to the healthy cohort and the association with lupus disease activity determined (Mann Whitney U Test, p < 0.05).

Results:

A statistically significant enrichment of a memory IL10 positive B cell subset (CD19+CD27+) with CD11c+CD25+HLA-DR+CD40hiCD86hi was found in the SLE cohort. This cell population was significantly associated with an inactive lupus disease state, suggestive of an immunoregulatory function. In the healthy cohort, a reciprocal increase in the transitional/naive B cell population negative for CD11c, CD25, CD40 and CD86 was found.

Secondly, a significant enrichment of the memory regulatory T cell population (CD4+CD45RO+CD25+Foxp3+) was present in the diseased cohort, especially during disease inactivity, with some of these cells being positive for CXCR5, a homing chemokine receptor to the lymph node germinal centre. Expression of CXCR5 is mechanistically relevant and signifies a potential regulatory role of these cells as the lymph node is an important lupus related microenvironment.

Conclusion:

A holistic multi-dimensional approach was able to distill the immunoregulatory components of the cSLE immunome. The identification of a novel regulatory B cell subset, typified by the presence of IL10, with phenotypic markers for antigen presentation (HLA-DR, CD86) and T-B cell interaction (CD25, CD40) suggests its potential regulatory role during direct cell-to-cell interaction. In addition, the concomitant increase in the memory regulatory T cell subset suggests at least a dual regulatory mechanism responsible for quiescent disease. Further mechanistic study of these subsets is necessary and have the dual translational potential of being used as a predictor of clinical fate and identification of new therapeutic targets.


Disclosure: J. G. Yeo, None; T. Arkachaisri, None; L. Das, None; J. H. T. Tan, None; J. Y. Leong, None; Y. J. A. Tan, None; L. Lai, None; L. D. T. Bathi, None; P. Chen, None; S. C. E. Lee, None; Y. X. Book, None; S. Albani, None.

To cite this abstract in AMA style:

Yeo JG, Arkachaisri T, Das L, Tan JHT, Leong JY, Tan YJA, Lai L, Bathi LDT, Chen P, Lee SCE, Book YX, Albani S. A Novel Regulatory Antigen Presenting B Cell and Memory Regulatory T Cell Subsets Are Enriched during the Quiescent Phase of Childhood Onset Systemic Lupus Erythematosus [abstract]. Arthritis Rheumatol. 2017; 69 (suppl 10). https://acrabstracts.org/abstract/a-novel-regulatory-antigen-presenting-b-cell-and-memory-regulatory-t-cell-subsets-are-enriched-during-the-quiescent-phase-of-childhood-onset-systemic-lupus-erythematosus/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2017 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/a-novel-regulatory-antigen-presenting-b-cell-and-memory-regulatory-t-cell-subsets-are-enriched-during-the-quiescent-phase-of-childhood-onset-systemic-lupus-erythematosus/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology